2022 / 01

Next Paper
DOI: 10.24075/brsmu.2022.005
Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Properties of RBD specific IgG from COVID-19 patients and Sputnik V vaccinated individuals

Generalova LV1, Grigoriev IV2, Vasina DV2, Tkachuk AP2, Kruzhkova IS2, Kolobukhina LV2, Burgasova OA1,2, Gushchin VA2
About authors

1 Рeoples’ Friendship University of Russia (RUDN University), Moscow, Russia

2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

Correspondence should be addressed: Vladimir A. Gushchin
Gamaleya, 18, str. 9, Moscow, Russia; moc.liamg@adainawow

About paper

Funding: this research was funded by the Ministry of Health of the Russian Federation, Government assignments number № АААА - А20-120113090054-6, Prof. Olga A. Burgasova was also supported by the RUDN University Strategic Academic Leadership Program.

Author contribution: LV Generalova, IV Grigoriev — research planning, experiments preparation and execution, data interpretation and paper draft preparation; IS Kruzhkova, LV Kolobukhina — data interpretation and paper draft preparation; DV Vasina, AP Tkachuk, OA Burgasova, VA Gushchin — research planning, data interpretation and paper draft preparation.

Compliance with ethical standards: the study was approved by the ethics committee of the First Moscow Infectious Diseases Hospital (protocol № 11/А dated November 16, 2020); informed consent was obtained from all study participants.

Received: 2022-01-23 Accepted: 2022-02-08 Published online: 2022-02-16
|
  1. Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis. 2020; 222: 1974–84.
  2. Tang J, Grubbs G, Lee Y, et al. Impact of convalescent plasma therapy on SARS-CoV-2 antibody profile in COVID-19 patients. Clin Infect Dis. 2021; ciab317.
  3. Baker KF, Hanrath AT, Schim van der Loeff I, et al. National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clin Med (Lond). 2021; 21 (2): 84–89.
  4. Paul KS Chan, Pak-Leong Lim, Esther YM Liu, et al. Antibody Avidity Maturation during Severe Acute Respiratory Syndrome– Associated Coronavirus Infection. J Infect Dis. 2005; 192 (1): 166–9.
  5. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11 (1): 2251.
  6. Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26 (6): 845–8.
  7. Kreer C, Zehner M, Weber T, et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell. 2020; 182 (4): 843–54.
  8. Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020; 369 (6504): 650–5.
  9. Piccoli L, Park Y, Tortorici M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike ReceptorBinding Domain by structure-guided high-resolution serology. Cell. 2020; 183 (4): 1024–42.
  10. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591, 639–44.